TESARO® logo_RGB_small.png
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
April 19, 2017 16:15 ET | TESARO, Inc.
ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerZEJULA is the only PARP inhibitor that has demonstrated a clinically...
TESARO® logo_RGB_small.png
Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year
April 07, 2017 08:30 ET | TESARO, Inc.
WALTHAM, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE)...